^
    3d
    Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=11, Terminated, The First Affiliated Hospital with Nanjing Medical University | N=33 --> 11 | Trial completion date: Jun 2028 --> Aug 2025 | Recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Jun 2025; Achieve the proof of concept.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    10d
    CLN-619-001: A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=440, Active, not recruiting, Cullinan Therapeutics Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • Datroway (datopotamab deruxtecan-dlnk) • CLN-619
    11d
    Optimization of velocity receptor transduction in CAR T cells. (PubMed, bioRxiv)
    We also observed a log-linear relationship between viral dose and transduction efficiency for a subset of VRs previously tested in various mouse models of human cancer, with VR5αIL8 and VR5αTNFα VRs consistently outperforming VR5αIL5 and V5 (full length native IL5 receptor). Overall, these findings establish an optimized and reproducible framework that offers valuable guidance for the future development and functional study of VR-CAR T cells in cellular therapies for solid tumors.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL5 (Interleukin 5)
    17d
    B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma (clinicaltrials.gov)
    P1, N=14, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    2ms
    A clinical trial to assess the safety, distribution, effects on certain immune cells and anti-leukaemia effects of LAVA-1266 in patients with acute myeloid leukaemia or certain types of myelodysplastic syndrome (ACTRN12624001214527)
    P1, N=50, Terminated, LAVA Therapeutics N.V. | Recruiting --> Terminated
    Trial termination
    |
    IL3RA (Interleukin 3 Receptor Subunit Alpha)
    2ms
    Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, AVM Biotechnology Inc | Trial completion date: Mar 2025 --> Mar 2032 | Trial primary completion date: Dec 2024 --> Dec 2031
    Trial completion date • Trial primary completion date
    |
    dexamethasone sodium phosphate (AVM0703)
    2ms
    The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies (clinicaltrials.gov)
    P1/2, N=144, Recruiting, AVM Biotechnology Inc | Trial completion date: Jun 2025 --> Dec 2026 | Trial primary completion date: Apr 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    TP53 mutation • TP53 mutation + Chr del(17p)
    |
    dexamethasone sodium phosphate (AVM0703)
    2ms
    ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML) (clinicaltrials.gov)
    P2, N=16, Terminated, TC Biopharm | N=53 --> 16 | Trial completion date: Dec 2025 --> Jul 2025 | Recruiting --> Terminated | Trial primary completion date: Dec 2025 --> Jul 2025; The Trial was early terminated due to deficiencies in the Achieve Protocol: V8.0 dated 19 January 2024.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    cyclophosphamide
    2ms
    B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma (clinicaltrials.gov)
    P1, N=14, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P1 trial • First-in-human
    3ms
    A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, Cullinan Therapeutics Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CLN-619
    3ms
    SUPLEXA-101: Study of SUPLEXA in Patients With Metastatic Solid Tumours and Haematologic Malignancies (clinicaltrials.gov)
    P1, N=46, Completed, Alloplex Biotherapeutics Inc | N=35 --> 46
    Enrollment change • First-in-human
    3ms
    A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune Diseases (clinicaltrials.gov)
    P1, N=44, Recruiting, Beijing GoBroad Hospital
    New P1 trial